April 23, 2026 12:14 ETÂ Â | Source:Â PridCor Therapeutics, LLC TUSCALOOSA, Ala., April 23, 2026 (GLOBE NEWSWIRE) — PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today.
Read More
TUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) — PridCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long COVID, today.
Read More
TUSCALOOSA, Ala., Sept. 23, 2025 (GLOBE NEWSWIRE) — PridCor Therapeutics today announced that Dr. David Putrino, principal investigator of the company’s SHIELD Study, participated.
Read More
September 04, 2025 10:32 ETÂ | Source:Â GlobalNewsWire-New Preprint:Â PridCor Therapeutics LLC has released a pre-print detailing a case series of 15 patients with Long COVID (LC).
Read More